Welcome to our dedicated page for Establishment Labs Holdings news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Holdings stock.
Establishment Labs Holdings Inc. (ESTA) is a leading global medical technology company, renowned for its innovation in the field of medical devices and aesthetics. Specializing in advanced silicone-filled breast and body shaping implants, the company has over 30 years of experience in breast implant manufacturing. Establishment Labs designs, develops, manufactures, and markets an extensive product portfolio that ensures safety and meets the current needs and preferences of plastic surgeons and patients.
Known for its flagship product, Motiva Implants®, Establishment Labs has set a benchmark in the industry for product innovation and safety. The company operates in multiple geographical segments, including Europe, Latin America, Asia-Pacific/Middle East, and other regions. Establishment Labs' products are distributed to medical distributors, physicians, hospitals, and clinics through direct sales channels.
Recent achievements include the continued global expansion of the Motiva Implants® brand and strategic partnerships aimed at advancing medical and aesthetic technology. With a strong focus on the future, the company is dedicated to pushing the boundaries of innovation and safety in medical devices.
Establishment Labs maintains a robust financial condition, driven by its commitment to quality and continuous improvement. The company’s ongoing projects include research and development initiatives aimed at introducing new and improved products that align with market demands.
For the latest updates and relevant information about Establishment Labs Holdings Inc., stay tuned to this page for the most recent news and developments.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported a second-quarter revenue of $32.0 million, up 205% year-over-year, achieving a quarterly record. The company raised its 2021 revenue guidance to $122 million to $126 million, a 44% to 49% increase from 2020. Operating expenses rose to $26.1 million, up 55% from the previous year, contributing to a net loss of $5.3 million. The company maintains a cash balance of $76.8 million. Additionally, notable advancements include the publication of a study on Motiva SmoothSilk implants demonstrating superior biocompatibility.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced the publication of its 2020 Corporate Social Responsibility annual review, marking the third anniversary of its NASDAQ listing. CEO Juan José Chacón-Quirós emphasized the company’s commitment to sustainability and governance, alongside financial goals. Key topics included the elevation of Women’s Health as a material focus, the achievement of carbon-neutral certifications, advocacy for women’s health, and highlights of its financial performance. The report aims to align with the 2030 UN Sustainable Development Goals and benchmark against industry peers.
Establishment Labs Holdings (NASDAQ: ESTA) will release its financial results for Q2 2021 on July 29, 2021, prior to market open. A conference call is scheduled for 8:30 am ET the same day to discuss these results. The company specializes in women's health, particularly in breast aesthetics, and offers Motiva Implants®, which are available in over 80 countries. Established in 2018, they received FDA approval for a clinical trial in the U.S. for these implants.
Establishment Labs Holdings (NASDAQ: ESTA) announced the appointment of Ann Custin and Bryan Slotkin to its Board of Directors, effective immediately. Founder and CEO Juan José Chacón-Quirós highlighted their governance experience as crucial for advancing the company's mission in women's health. Custin, former CFO at Siemens Healthineers, and Slotkin, a partner at PJT Partners, bring extensive industry and financial expertise. This leadership change aims to enhance innovation and market expansion, aligning with the company’s commitment to improving women's health through differentiated technology.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced CFO Renee Gaeta's departure effective July 30, 2021, with Raj Denhoy appointed as Interim CFO. The company expects second-quarter 2021 revenues between $31 million and $32 million, reflecting a 196% to 206% growth year-over-year. Gaeta expressed gratitude for her tenure, noting the company’s significant growth, including completion of an FDA trial and plans for a third manufacturing facility. Establishment Labs remains committed to its goal of becoming a leader in breast aesthetics and reconstruction.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has commenced construction on its Sulayöm Innovation Campus in Costa Rica, aimed at enhancing its manufacturing and R&D capabilities in the breast aesthetics market. The project, split into two phases and costing approximately $35 million, is expected to generate up to 1,000 new jobs. The facility will support global growth plans and sustainability initiatives, as the company aims to cater to over half of the worldwide market for Motiva Implants. The groundbreaking marks a significant step in the company’s expansion strategy.
Establishment Labs Holdings (NASDAQ: ESTA) held a groundbreaking ceremony for its Sulayöm Innovation Campus in Costa Rica, which will span approximately 145,000 square feet. This new facility aims to enhance manufacturing, R&D, and training capabilities, supporting the company’s growth in breast aesthetics. The first phase of construction is projected to cost $35 million, primarily financed through local credit. The campus will create 1,000 new jobs and allows the company to expand its global footprint, aiming to supply over half of the worldwide market for Motiva Implants.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced results from a pivotal study on breast implant surfaces affecting immune responses. Conducted by MIT researchers, the study published in Nature Biomedical Engineering reveals that the patented Motiva® SmoothSilk® surface minimizes the foreign body response compared to rough or smooth alternatives. Findings indicate lower macrophage activity and healthier tissue capsules associated with SmoothSilk implants. These results could reshape the breast implant industry by enhancing biocompatibility, potentially reducing complications and improving patient outcomes.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a company specializing in women's health, will feature CEO Juan José Chacón-Quirós and CFO Renee Gaeta at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. Their presentation is scheduled for June 4 at 2:00 pm ET. A live webcast will be accessible on the Establishment Labs investor relations website, with an archived version available later. The company designs and manufactures silicone gel-filled breast implants under the Motiva Implants® brand, complying with FDA and ISO standards, and has a presence in over 80 countries.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has appointed Pratip Dastidar as the Head of Global Operations, aiming to enhance operational transformation and global scaling. With a robust background from ServiceMaster and Salesforce, Dastidar's experience is expected to drive digital initiatives. CEO Juan José Chacón-Quirós emphasized the alignment of operations with growth strategies. Salvador Dada will return as Head of Special Projects, overseeing new manufacturing and R&D facilities in Costa Rica to support expansion into markets like China and the U.S.
FAQ
What is the current stock price of Establishment Labs Holdings (ESTA)?
What is the market cap of Establishment Labs Holdings (ESTA)?
What does Establishment Labs Holdings Inc. specialize in?
What is the flagship product of Establishment Labs?
In which regions does Establishment Labs operate?
How does Establishment Labs distribute its products?
What are the recent achievements of Establishment Labs?
What is the focus of Establishment Labs' ongoing projects?
How long has Establishment Labs been in the breast implant manufacturing industry?
What sets Motiva Implants® apart from other products in the market?
Is Establishment Labs a publicly traded company?